![CF Pharma Cisatracurium Besylate Header](https://www.pharmacompass.com/image/flap/cf-pharma-header-desktop-cisatracurium-besylategif-6769.gif)
![CF Pharma Cisatracurium Besylate Header](https://www.pharmacompass.com/image/flap/cf-pharma-header-mobile-cisatracurium-besylate-gif-11116.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
1. 51w89
2. Cisatracurium
3. Cisatracurium Besilate
4. Nimbex
1. 96946-42-8
2. Nimbex
3. Cisatracurium Besilate
4. Cisatracurium (besylate)
5. 51w89
6. Cisatracurium Besylate [usan]
7. Cisatracurium (as Besilate)
8. 80ys8o1mbs
9. Cisatracurium Besilate [inn]
10. Chebi:3721
11. (1r,1'r,2r,2'r)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) Benzenesulfonate
12. 96946-42-8 (besylate)
13. (1r,2r)-2-(2-carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium Benzenesulfonate, Pentamethylene Ester
14. (1r-cis,1'r-cis)-atracurium Besylate
15. 51-w89
16. 51w-89
17. 51-w-89
18. Cisatracurium Besilate (inn)
19. Nimbex Preservative Free
20. Cis-atracurium Besylate
21. Unii-80ys8o1mbs
22. Nimbium
23. Atracurium Besylate 1r-cis,1r'-cis Form
24. Nimbex Forte
25. Ncgc00017127-01
26. Cas-64228-81-5
27. Nimbex (tn)
28. Cisatracurium Besylate Preservative Free
29. Cis-atracurium Besilate
30. Isoquinolinium,2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-,(1r,1'r,2r,2'r)-, Dibenzenesulfonate
31. Y78ps7mede
32. Schembl40669
33. Cisatracurium Besylate (usp)
34. Cisatracurium Dibenzenesulfonate
35. Cisatracurium Besylate (nimbex)
36. Chembl1200641
37. Cisatracurium Besylate (~90%)
38. Dtxsid10895045
39. Hms3715p04
40. Hms3884l07
41. Cisatracurium Besylate [mi]
42. Benzenesulfonate;5-[3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate
43. Ex-a2646
44. Mfcd00871018
45. S2113
46. Cisatracurium Besylate [vandf]
47. Akos026750111
48. Cisatracurium Besilate [mart.]
49. Ccg-221271
50. Cisatracurium Besilate [who-dd]
51. Cisatracurium Besylate [usp-rs]
52. (1r,2r,1'r,2'r)-atracurium Besylate
53. Bs-17985
54. Hy-13596
55. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulfonate, (1r-(1alpha,2alpha(1'r(sup *),2'r(sup *))))-
56. Cisatracurium Besylate [orange Book]
57. Cisatracurium Besilate [ep Monograph]
58. Sw222230-1
59. Cisatracurium Besylate [usp Monograph]
60. 51 W89
61. D00759
62. Q267669
63. W-60404
64. Z2216208615
65. Atracurium Besylate, (1r,1'r,2r,2'r)-(+/-)-
66. Cisatracurium Besilate, Europepharmacopoeia (ep) Reference Standard
67. Cisatracurium Besylate, United States Pharmacopeia (usp) Reference Standard
68. Cisatracurium For Peak Identification, Europepharmacopoeia (ep) Reference Standard
69. Cisatracurium For System Suitability, Europepharmacopoeia (ep) Reference Standard
70. (1r,1'r,2r,2'r)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)benzenesulfonate
71. (1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium Dibenzenesulfonate
72. (1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
73. (1r-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
74. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-, Benzenesulfonate (1:2)
75. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-, Dibenzenesulfonate
76. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r,1'r,2r,2'r)-rel, Dibenzenesulfonate
77. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulfonate, (1r-(1.alpha.,2.alpha.(1'r*,2'r*)))-
78. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulphonate, (1r-(1.alpha.,2.alpha.(1'r*,2'r*)))-
Molecular Weight | 1243.5 g/mol |
---|---|
Molecular Formula | C65H82N2O18S2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 26 |
Exact Mass | 1242.50040612 g/mol |
Monoisotopic Mass | 1242.50040612 g/mol |
Topological Polar Surface Area | 258 Ų |
Heavy Atom Count | 87 |
Formal Charge | 0 |
Complexity | 1560 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 6 | |
---|---|
Drug Name | Cisatracurium besylate |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml |
Market Status | Prescription |
Company | Sandoz |
2 of 6 | |
---|---|
Drug Name | Nimbex |
Drug Label | NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10... |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml |
Market Status | Prescription |
Company | Abbvie |
3 of 6 | |
---|---|
Drug Name | Nimbex preservative free |
Drug Label | Cisatracurium besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10isomers... |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml; eq 10mg base/ml |
Market Status | Prescription |
Company | Abbvie |
4 of 6 | |
---|---|
Drug Name | Cisatracurium besylate |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml |
Market Status | Prescription |
Company | Sandoz |
5 of 6 | |
---|---|
Drug Name | Nimbex |
Drug Label | NIMBEX (cisatracurium besylate) is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10... |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml |
Market Status | Prescription |
Company | Abbvie |
6 of 6 | |
---|---|
Drug Name | Nimbex preservative free |
Drug Label | Cisatracurium besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is one of 10isomers... |
Active Ingredient | Cisatracurium besylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2mg base/ml; eq 10mg base/ml |
Market Status | Prescription |
Company | Abbvie |
Neuromuscular Blocking Agents
Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. (See all compounds classified as Neuromuscular Blocking Agents.)